Welcome to our dedicated page for Neuroone Med Technologies news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on Neuroone Med Technologies stock.
NeuroOne Medical Technologies Corp (NMTC) develops cutting-edge thin film electrode solutions for neurological diagnostics and treatment. This page provides centralized access to official company news, including product advancements, regulatory milestones, and strategic developments in the neuromodulation sector.
Investors and healthcare professionals will find timely updates on NMTC's innovations in continuous EEG monitoring, brain stimulation technologies, and minimally invasive therapeutic devices. The curated news collection offers insights into how the company addresses complex neurological disorders like epilepsy and Parkinson's disease.
Key updates include FDA clearances, research partnerships with medical institutions, and advancements in electrode technology for precise neurodiagnostics. All content is sourced from verified releases to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page to stay informed about NMTC's contributions to medical technology and its evolving role in improving neurological care. Check regularly for objective updates on developments impacting the neuromodulation industry and patient treatment paradigms.
NeuroOne Medical Technologies (NASDAQ: NMTC) reported its financial results for Q2 FY2024, ending March 31, 2024. Product revenue increased to $1,377,000 from $466,000 in Q2 FY2023. The company raised an additional $2 million through the ATM Program. Key product updates include the commercial launch of the OneRF Ablation System and expanded use of the Evo sEEG system by Zimmer Biomet.
R&D expenses decreased to $1.3 million, while SG&A expenses rose to $2 million. Total operating expenses were $3.3 million. The net loss dropped to $2.9 million from $3.5 million in Q2 FY2023. Cash and cash equivalents fell to $2.4 million from $5.3 million as of September 2023.
Key upcoming milestones include transitioning to OneRF electrodes, enhancing the drug delivery program, and refining the spinal cord stimulation program.
NeuroOne Medical Technologies (NMTC) will host a conference call and webcast on May 14, 2024, to discuss the financial results for its second quarter of fiscal year 2024 and provide a corporate update. The company focuses on improving surgical care options and outcomes for patients with neurological disorders.
FAQ
What is the current stock price of Neuroone Med Technologies (NMTC)?
What is the market cap of Neuroone Med Technologies (NMTC)?
